{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:44:05Z","timestamp":1790765045230,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ebiom.2022.104322","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T13:38:01Z","timestamp":1667309881000},"page":"104322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7866-2651","authenticated-orcid":false,"given":"Nomathemba","family":"Chandiwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Farouk","family":"Chughlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byungsu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yengiwe","family":"Dineka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Arbe-Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Windgassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Abla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Claire","family":"Marrast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem Daniel","family":"Francois Venter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104322_bib1","series-title":"Coronavirus resource center","year":"2021"},{"key":"10.1016\/j.ebiom.2022.104322_bib2","article-title":"Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study","volume":"6","author":"Augustin","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ebiom.2022.104322_bib3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3851\/IMP2128","article-title":"Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households","volume":"17","author":"Carrat","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ebiom.2022.104322_bib4","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2020.22813","article-title":"Therapy for early COVID-19: a critical need","volume":"324","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2022.104322_bib5","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.935952","article-title":"Editorial: current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients","volume":"28","author":"Parums","year":"2022","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ebiom.2022.104322_bib6","series-title":"Therapeutic management of nonhospitalized adults with COVID-19","year":"2021"},{"key":"10.1016\/j.ebiom.2022.104322_bib7","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1136\/bmj.n2697","article-title":"Covid-19: UK becomes first country to authorise antiviral molnupiravir","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ebiom.2022.104322_bib8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/cpt.1909","article-title":"Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics","volume":"108","author":"Arshad","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2022.104322_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pt.2020.10.003","article-title":"Repurposing antimalarials to tackle the COVID-19 pandemic","volume":"37","author":"Krishna","year":"2021","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ebiom.2022.104322_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Munoz-Fontela","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104322_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2875-12-70","article-title":"Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials","volume":"12","author":"Duparc","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.ebiom.2022.104322_bib12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1475-2875-11-260","article-title":"Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa","volume":"11","author":"Zwang","year":"2012","journal-title":"Malar J"},{"key":"10.1016\/j.ebiom.2022.104322_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.ebiom.2022.104322_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ebiom.2022.104322_bib15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/QAD.0000000000001020","article-title":"Interferon-free treatment with sofosbuvir\/daclatasvir achieves sustained virologic response in 100% of HIV\/hepatitis C virus-coinfected patients with advanced liver disease","volume":"30","author":"Mandorfer","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2022.104322_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007072","article-title":"Yellow fever virus is susceptible to sofosbuvir both in\u00a0vitro and in\u00a0vivo","volume":"13","author":"de Freitas","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ebiom.2022.104322_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ebiom.2022.104322_bib18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/cbdd.13091","article-title":"Sofosbuvir as treatment against dengue?","volume":"91","author":"Gan","year":"2018","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.ebiom.2022.104322_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01389-18","article-title":"Beyond members of the flaviviridae family, sofosbuvir also inhibits Chikungunya virus replication","volume":"63","author":"Ferreira","year":"2019","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.ebiom.2022.104322_bib20","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.ebiom.2022.104322_bib21","article-title":"Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ebiom.2022.104322_bib23","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/cpmc.108","article-title":"An in\u00a0vitro microneutralization assay for SARS-CoV-2 serology and drug screening","volume":"58","author":"Amanat","year":"2020","journal-title":"Curr Protoc Microbiol"},{"key":"10.1016\/j.ebiom.2022.104322_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-015-1330-0","article-title":"Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza","volume":"16","author":"Powers","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104322_bib25","series-title":"WHO R&D Blueprint novel coronavirus COVID-19 therapeutic trial synopsis","year":"2020"},{"key":"10.1016\/j.ebiom.2022.104322_bib26","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A\u00a0minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104322_bib27","first-page":"746","article-title":"An introduction to multiplicity issues in clinical trials: the what, why, when and how","volume":"46","author":"Li","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ebiom.2022.104322_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ebiom.2022.104322_bib29","first-page":"52","article-title":"Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19","volume":"6","author":"Pepperrell","year":"2020","journal-title":"J\u00a0Virus Erad"},{"key":"10.1016\/j.ebiom.2022.104322_bib30","doi-asserted-by":"crossref","first-page":"e877","DOI":"10.1097\/MEG.0000000000002287","article-title":"Safety and efficacy of sofosbuvir\/ledipasvir and sofosbuvir\/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis","volume":"33","author":"El Kassas","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ebiom.2022.104322_bib31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5009\/gnl18269","article-title":"High efficacy and safety of flat-dose ribavirin plus sofosbuvir\/daclatasvir in genotype 3 cirrhotic patients","volume":"14","author":"Pellicelli","year":"2020","journal-title":"Gut Liver"},{"key":"10.1016\/j.ebiom.2022.104322_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jvh.13032","article-title":"Safety and efficacy of combined sofosbuvir\/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4","volume":"26","author":"Abdel Ghaffar","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.ebiom.2022.104322_bib33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acsinfecdis.2c00091","article-title":"Pyronaridine protects against SARS-CoV-2 infection in mouse","volume":"8","author":"Puhl","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104322_bib34","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cmi.2021.12.026","article-title":"Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicenter, placebo-controlled trial clinical trial","volume":"28","author":"Bosaeed","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ebiom.2022.104322_bib35","first-page":"12575","article-title":"Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19","volume":"13","author":"Ruzhentsova","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ebiom.2022.104322_bib36","article-title":"Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review","volume":"8","author":"Srinivasan","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104322_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105631","article-title":"Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in covid-19 patients: an exploratory randomized, controlled trial","volume":"157","author":"Lou","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ebiom.2022.104322_bib38","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1111\/bcp.15227","article-title":"Pharmacokinetic characterization of favipiravir in patients with COVID-19","volume":"88","author":"Gulhan","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ebiom.2022.104322_bib39","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1111\/bcp.14619","article-title":"Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis","volume":"87","author":"Rajoli","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ebiom.2022.104322_bib40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/cpt.2463","article-title":"An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2","volume":"111","author":"Walker","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2022.104322_bib41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jac\/dkaa501","article-title":"Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial","volume":"76","author":"Roozbeh","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ebiom.2022.104322_bib42","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/jac\/dkab433","article-title":"Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)","volume":"77","author":"Mobarak","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ebiom.2022.104322_bib43","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/jac\/dkaa332","article-title":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial","volume":"75","author":"Abbaspour Kasgari","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ebiom.2022.104322_bib44","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/jmv.26103","article-title":"Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19","volume":"92","author":"Carmo","year":"2020","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.ebiom.2022.104322_bib45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104322_bib46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:20:16Z","timestamp":1762456816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422005047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":45,"alternative-id":["S2352396422005047"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104322","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104322"}}